Zobrazeno 1 - 10
of 3 118
pro vyhledávání: '"chimeric antigen receptor T cell"'
Publikováno v:
陆军军医大学学报, Vol 46, Iss 17, Pp 1951-1958 (2024)
Objective To use superparamagnetic iron oxide nanoparticles (SPIONs) to label chimeric antigen receptor (CAR) T cells targeting carcinoembryonic antigen (CEA), and perform magnetic resonance imaging (MRI) to real time trace CEA CAR-T cells in vivo. M
Externí odkaz:
https://doaj.org/article/82f0ee9c17b44669b1d55df548b5b1a5
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-4 (2024)
Abstract Multiple classes of therapies targeting claudin-18 isoform 2 (CLDN18.2) are under development for the treatment of advanced gastroesophageal adenocarcinoma and other solid tumors. At the 2024 American Society of Clinical Oncology (ASCO) Annu
Externí odkaz:
https://doaj.org/article/7c852dae49844599adeca9f938191bc2
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 51, Iss 8, Pp 648-654 (2024)
Tumor immunotherapy occupies a pivotal position in the field of hematological malignancies. Chimeric antigen receptor (CAR) T-cell therapy has established a new therapeutic pattern for hematological immunotherapy and achieved satisfactory clinical re
Externí odkaz:
https://doaj.org/article/356ab3a80d3b45df983e66a0bbd94215
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Purpose Chimeric antigen receptor T-cell (CART) therapy has shown clinical efficacy in refractory and relapsed large B-cell lymphomas, but is associated with serious acute and long-term toxicities. To understand the patient perspective, we m
Externí odkaz:
https://doaj.org/article/d698902dbf064ab5803aeb8e9a30c975
Publikováno v:
Current Oncology, Vol 31, Iss 8, Pp 4338-4345 (2024)
Chimeric Antigen Receptor T-cell (CAR-T) therapy uses genetically engineered T-cells with specific binding sites. This therapy allows for tumor specificity and durable treatment responses for patients with hematological malignancies. In this review,
Externí odkaz:
https://doaj.org/article/e1b3a89939984ba5bd3fc892e6b4dbc2
Publikováno v:
Zhongguo aizheng zazhi, Vol 34, Iss 7, Pp 639-649 (2024)
Background and purpose: Chimeric antigen receptor T (CAR-T) cell therapy has shown remarkable efficacy in treating hematological and lymphatic system tumors, but its effectiveness in solid tumors is relatively poor, which is partly attributed to targ
Externí odkaz:
https://doaj.org/article/acd14c4bb0894818bccd4f897a19e5d6
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2024)
Abstract Chimeric antigen receptor-T cell therapy, a groundbreaking cancer treatment, has achieved remarkable success against hematologic malignancies. However, CAR-T monotherapy faces challenges in certain cases, including treatment tolerance and re
Externí odkaz:
https://doaj.org/article/f328d036fd1b4482a0a90bd11f67b176
Autor:
Lian-Fang Pu, Hui-Min Zheng, Xiang-Jiang Feng, Alice Charwudzi, Xue Liang, Lin-Hui Hu, Yang-Yang Ding, Ze-Lin Liu, Ya Liao, Shu-Dao Xiong
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background CD19-targeted chimeric antigen receptor T (CAR-T) cell therapy stands out as a revolutionary intervention, exhibiting remarkable remission rates in patients with refractory/relapsed (R/R) B-cell malignancies. However, the potentia
Externí odkaz:
https://doaj.org/article/e50289f53c6f44b2a90bdaf69002d041
Autor:
Esther Choi, BS, Cuong V. Nguyen, MD
Publikováno v:
JAAD Case Reports, Vol 52, Iss , Pp 42-45 (2024)
Externí odkaz:
https://doaj.org/article/c328054274a048bab92adc7b39b774c4
Autor:
WANG Yiyang, LÜ Liangjing
Publikováno v:
Zhenduanxue lilun yu shijian, Vol 23, Iss 03, Pp 263-269 (2024)
Systemic lupus erythematosus (SLE) is a complex autoimmune disease for which traditional treatments often show limited efficacy in severe and refractory cases. Recently, chimeric antigen receptor (CAR) T cell therapy has emerged as a novel immunother
Externí odkaz:
https://doaj.org/article/a2acd7ad8fbe4ed597ea03f34e9dd3a6